^
    9ms
    Comparison of cell of origin (COO) classification of DLBCL patients using HTG EdgeSeq platform with conventional Han's algorithm (ECP 2023)
    Our study demonstrated similar concordance with the HTG assay. As NGS platforms become more widely available in pathology, RNA expression-based assays are expected to become more significant in diagnostics and replace IHC-based methods of classification.
    Clinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6)
    |
    HTG EdgeSeq DLBCL Cell of Origin Assay
    over1year
    Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies (ASH 2022)
    Patients with PD-L1 gene amplification, PD-L1+ tumor cells, and high mRNA levels of CD3D, HLA-DRA, and LAG3 in baseline tumor tissue may be more responsive to zanubrutinib and tislelizumab combination therapy. A high mRNA level of REL or mutations in TP53 may contribute to resistance of zanubrutinib and tislelizumab combination therapy. Due to the limited number of samples, results must be interpreted with caution.
    Combination therapy • Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • CD3D (CD3d Molecule) • REL (REL Proto-Oncogene)
    |
    PD-L1 expression • TP53 mutation • CD8 expression • PD-L1 amplification
    |
    VENTANA PD-L1 (SP263) Assay • HTG EdgeSeq DLBCL Cell of Origin Assay • Ventana CONFIRM anti-CD8 (SP57) Rabbit Monoclonal Primary Antibody
    |
    Tevimbra (tislelizumab) • Brukinsa (zanubrutinib)
    almost2years
    DLBCL cell of origin typing and whole transcriptome analysis using single slides with HTG EdgeSeq. (ASCO 2022)
    Combined COO typing and whole transcriptome analysis from a single slide efficiently uses precious patient tissue. Longitudinal core needle sampling may yield insights into tumor evolution and therapeutic mechanisms of action across the DLBCL treatment landscape.
    BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    MYC overexpression
    |
    HTG EdgeSeq DLBCL Cell of Origin Assay